The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M04 | Antigout preparations | |
| 3 | M04A | Antigout preparations | |
| 4 | M04AC | Preparations with no effect on uric acid metabolism | |
| 5 | M04AC01 | Colchicine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 1 mg |
| PAREN - Parenteral | 1 mg |
| Active Ingredient | Description | |
|---|---|---|
| Colchicine |
Colchicine is considered to act against the inflammatory response to urate crystals, by possibly inhibiting the migration of granulocytes into the inflamed area. Other properties of colchicine, such as interaction with the microtubules, could also contribute to the operation. Onset of action is approximately 12 hours after oral administration and is maximal after 1 to 2 days. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| COLCHICINA | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| COLCHICINE Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
